AZNAstraZenecaRunning, no new patients
A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
Advanced or Metastatic NSCLC
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Jul 2024, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 2
- Patients
- 39 (final count)
- Started
- Jun 21, 2023
- Main results expected
- Jul 29, 2024
- Fully finished
- Jan 1, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective response rate (ORR)
Measured over: At month 6 after the last patient's first dose (approximately 18 months).
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2024-07-29, no fading
Raw record changes
- none yet
Trial ID NCT05941897 · record last updated 2026-09-09 · checked 2026-11-09 15:47 UTC